Cargando…

Liquid-Solid Phase-Inversion PLGA Implant for the Treatment of Residual Tumor Tissue after HIFU Ablation

BACKGROUND: HIFU has been shown to be a more suitable alternative for the treatment of primary solid tumors and metastatic diseases than other focal heat ablation techniques due to its noninvasive and extracorporeal nature. However, similar to other focal heat ablation techniques, HIFU is still in n...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Juan, Krupka, Tianyi, Yao, Jinpeng, Wang, Ronghui, Jiang, Lin, Zhou, Yang, Zuo, Guoqing, Wang, Zhibiao, Dai, Lili, Ren, Jianli, Zheng, Yuanyi, Wang, Dong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4339192/
https://www.ncbi.nlm.nih.gov/pubmed/25710485
http://dx.doi.org/10.1371/journal.pone.0117358
_version_ 1782358853322539008
author Li, Juan
Krupka, Tianyi
Yao, Jinpeng
Wang, Ronghui
Jiang, Lin
Zhou, Yang
Zuo, Guoqing
Wang, Zhibiao
Dai, Lili
Ren, Jianli
Zheng, Yuanyi
Wang, Dong
author_facet Li, Juan
Krupka, Tianyi
Yao, Jinpeng
Wang, Ronghui
Jiang, Lin
Zhou, Yang
Zuo, Guoqing
Wang, Zhibiao
Dai, Lili
Ren, Jianli
Zheng, Yuanyi
Wang, Dong
author_sort Li, Juan
collection PubMed
description BACKGROUND: HIFU has been shown to be a more suitable alternative for the treatment of primary solid tumors and metastatic diseases than other focal heat ablation techniques due to its noninvasive and extracorporeal nature. However, similar to other focal heat ablation techniques, HIFU is still in need of refinements due to tumor recurrence. METHODS: In this work, we investigated the effectiveness of an adjunct treatment regimen using doxorubicin (DOX)-loaded, injectable, in situ-forming, and phase-inverting PLGA as the second line of defense after HIFU ablation to destroy detrimental residual tumors and to prevent tumor recurrence. All of the statistical analyses were performed using the Statistical Package for the Social Sciences 18.0(SPSS, Inc., Chicago, IL, USA), and p< 0.05 was considered statistically significant. All of the results are presented as the means ± STDEV (standard deviation). For multiple comparisons, ANOVA (differences in tumor volumes, growth rates, apoptosis, proliferation indexes, and Bcl-2 and Bax protein levels) was used when the data were normally distributed with homogenous variance, and rank sum tests were used otherwise. Once significant differences were detected, Student-t tests were used for comparisons between two groups. RESULTS: Our results revealed that DOX diffused beyond the ablated tissue regions and entered tumor cells that were not affected by the HIFU ablation. Our results also show that HIFU in concert with DOX-loaded PLGA led to a significantly higher rate of tumor cell apoptosis and a lower rate of tumor cell proliferation in the areas beyond the HIFU-ablated tissues and consequently caused significant tumor volume shrinkage (tumor volumes:0.26±0.1,1.09±0.76, and 1.42±0.9cm(3) for treatment, sham, and no treatment control, respectively). CONCLUSIONS: From these results, we concluded that the intralesional injection of DOX-loaded PLGA after HIFU ablation is significantly more effective than HIFU alone for the treatment of solid tumors.
format Online
Article
Text
id pubmed-4339192
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-43391922015-03-04 Liquid-Solid Phase-Inversion PLGA Implant for the Treatment of Residual Tumor Tissue after HIFU Ablation Li, Juan Krupka, Tianyi Yao, Jinpeng Wang, Ronghui Jiang, Lin Zhou, Yang Zuo, Guoqing Wang, Zhibiao Dai, Lili Ren, Jianli Zheng, Yuanyi Wang, Dong PLoS One Research Article BACKGROUND: HIFU has been shown to be a more suitable alternative for the treatment of primary solid tumors and metastatic diseases than other focal heat ablation techniques due to its noninvasive and extracorporeal nature. However, similar to other focal heat ablation techniques, HIFU is still in need of refinements due to tumor recurrence. METHODS: In this work, we investigated the effectiveness of an adjunct treatment regimen using doxorubicin (DOX)-loaded, injectable, in situ-forming, and phase-inverting PLGA as the second line of defense after HIFU ablation to destroy detrimental residual tumors and to prevent tumor recurrence. All of the statistical analyses were performed using the Statistical Package for the Social Sciences 18.0(SPSS, Inc., Chicago, IL, USA), and p< 0.05 was considered statistically significant. All of the results are presented as the means ± STDEV (standard deviation). For multiple comparisons, ANOVA (differences in tumor volumes, growth rates, apoptosis, proliferation indexes, and Bcl-2 and Bax protein levels) was used when the data were normally distributed with homogenous variance, and rank sum tests were used otherwise. Once significant differences were detected, Student-t tests were used for comparisons between two groups. RESULTS: Our results revealed that DOX diffused beyond the ablated tissue regions and entered tumor cells that were not affected by the HIFU ablation. Our results also show that HIFU in concert with DOX-loaded PLGA led to a significantly higher rate of tumor cell apoptosis and a lower rate of tumor cell proliferation in the areas beyond the HIFU-ablated tissues and consequently caused significant tumor volume shrinkage (tumor volumes:0.26±0.1,1.09±0.76, and 1.42±0.9cm(3) for treatment, sham, and no treatment control, respectively). CONCLUSIONS: From these results, we concluded that the intralesional injection of DOX-loaded PLGA after HIFU ablation is significantly more effective than HIFU alone for the treatment of solid tumors. Public Library of Science 2015-02-24 /pmc/articles/PMC4339192/ /pubmed/25710485 http://dx.doi.org/10.1371/journal.pone.0117358 Text en © 2015 Li et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Li, Juan
Krupka, Tianyi
Yao, Jinpeng
Wang, Ronghui
Jiang, Lin
Zhou, Yang
Zuo, Guoqing
Wang, Zhibiao
Dai, Lili
Ren, Jianli
Zheng, Yuanyi
Wang, Dong
Liquid-Solid Phase-Inversion PLGA Implant for the Treatment of Residual Tumor Tissue after HIFU Ablation
title Liquid-Solid Phase-Inversion PLGA Implant for the Treatment of Residual Tumor Tissue after HIFU Ablation
title_full Liquid-Solid Phase-Inversion PLGA Implant for the Treatment of Residual Tumor Tissue after HIFU Ablation
title_fullStr Liquid-Solid Phase-Inversion PLGA Implant for the Treatment of Residual Tumor Tissue after HIFU Ablation
title_full_unstemmed Liquid-Solid Phase-Inversion PLGA Implant for the Treatment of Residual Tumor Tissue after HIFU Ablation
title_short Liquid-Solid Phase-Inversion PLGA Implant for the Treatment of Residual Tumor Tissue after HIFU Ablation
title_sort liquid-solid phase-inversion plga implant for the treatment of residual tumor tissue after hifu ablation
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4339192/
https://www.ncbi.nlm.nih.gov/pubmed/25710485
http://dx.doi.org/10.1371/journal.pone.0117358
work_keys_str_mv AT lijuan liquidsolidphaseinversionplgaimplantforthetreatmentofresidualtumortissueafterhifuablation
AT krupkatianyi liquidsolidphaseinversionplgaimplantforthetreatmentofresidualtumortissueafterhifuablation
AT yaojinpeng liquidsolidphaseinversionplgaimplantforthetreatmentofresidualtumortissueafterhifuablation
AT wangronghui liquidsolidphaseinversionplgaimplantforthetreatmentofresidualtumortissueafterhifuablation
AT jianglin liquidsolidphaseinversionplgaimplantforthetreatmentofresidualtumortissueafterhifuablation
AT zhouyang liquidsolidphaseinversionplgaimplantforthetreatmentofresidualtumortissueafterhifuablation
AT zuoguoqing liquidsolidphaseinversionplgaimplantforthetreatmentofresidualtumortissueafterhifuablation
AT wangzhibiao liquidsolidphaseinversionplgaimplantforthetreatmentofresidualtumortissueafterhifuablation
AT dailili liquidsolidphaseinversionplgaimplantforthetreatmentofresidualtumortissueafterhifuablation
AT renjianli liquidsolidphaseinversionplgaimplantforthetreatmentofresidualtumortissueafterhifuablation
AT zhengyuanyi liquidsolidphaseinversionplgaimplantforthetreatmentofresidualtumortissueafterhifuablation
AT wangdong liquidsolidphaseinversionplgaimplantforthetreatmentofresidualtumortissueafterhifuablation